Pulmatrix Reports 2024 Financials and Merger Plans

TipRanksMar 24 23:57 ET

Pulmatrix | 10-K: Annual report

SECMar 21 08:21 ET · Announcements

Express News | Pulmatrix FY24 EPS $(2.62) Up From $(3.87) YoY; Revenue $7.8M Up From $7.3M YoY

BenzingaMar 21 08:11 ET

Pulmatrix: Merger With Cullgen Anticipated to Close in 1H >PULM

Dow JonesMar 21 08:09 ET

Pulmatrix Bears No Further Fincl Responsibility for Development of PUR1900 and Will Receive 2% Royalties on Any Potential Future Net Sales by Cipla Outside U.S. >PULM

Dow JonesMar 21 08:07 ET

Pulmatrix Has Stopped Patient Enrollment for Phase 2b Study of PUR1900 While Cipla Has Continued Their Phae 2 Trial Outside U.S. >PULM

Dow JonesMar 21 08:06 ET